## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.46 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($337.85)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Utah Lands $615M Stryker Expansion**
- Source: Business Facilities | 20251216T213115 | Bullish | Relevance: 100%
- Stryker, a global medical technology company, plans to expand its operations in Salt Lake City, Utah, investing $615.6 million over two decades and adding 862 jobs. The expansion is supported by an Economic Development Tax Increment Financing (EDTIF) program from the Utah Governor’s Office of Economic Opportunity. This move reinforces Utah's role in the life sciences sector and highlights the state's skilled workforce and innovative environment.

**2. Stryker Utah expansion expected to bring over $615M in investments, 862 new jobs**
- Source: KSL NewsRadio | 20251216T130900 | Bullish | Relevance: 100%
- Medical technology company Stryker announced a major expansion of its Salt Lake City operations, promising over $615 million in investments and 862 new jobs over the next two decades. This growth is supported by the Utah Governor’s Office of Economic Opportunity through a post-performance tax reduction incentive. Both Stryker and local officials highlighted Utah's strong talent pool and innovation-friendly environment as key drivers for this expansion.

**3. Stryker Utah expansion expected to bring over $615M in investments, 862 new jobs**
- Source: KSL.com | 20251216T021535 | Bullish | Relevance: 100%
- Medical technology company Stryker announced a significant expansion of its Salt Lake City operations, projecting over $615 million in investments and the creation of 862 new jobs over the next two decades. This growth is supported by a post-performance tax reduction from Utah's Economic Development Tax Increment Financing program, highlighting the state's talent pool and innovation-friendly environment. The expansion is celebrated by local officials as a boost for Salt Lake City families and the regional economy, reinforcing the city's role as a hub for medical technology advancements.

**4. Corient Private Wealth LLC Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251215T095935 | Bullish | Relevance: 100%
- Corient Private Wealth LLC significantly increased its holdings in Stryker Corporation (NYSE:SYK) by 2.6% in the second quarter, bringing its total stake to 1,127,559 shares valued at approximately $446.1 million. This makes Stryker the 24th largest holding for Corient. Other major institutional investors, including Vanguard Group Inc. and State Street Corp, also increased their positions, while company insiders have sold a considerable number of shares recently.

**5. Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88**
- Source: Simply Wall Street | 20251214T140801 | Bullish | Relevance: 100%
- Stryker Corporation (NYSE:SYK) has announced an increase in its periodic dividend to $0.88, effective January 30th, representing a 4.8% rise from the previous year. Although the dividend yield is relatively low at 0.9%, the payment is well-covered by earnings, with a projected payout ratio of 25% by next year. The company has a solid track record of consistent dividend growth and strong earnings per share, making it an attractive income stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $35M sold (6 transactions in 90 days).
2. Long-term trend broken: trading 6.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 23.5x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $134.5B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 23.5 |
| Current P/E | 26.0 |
| YoY Growth | 10.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.4% to -2.8% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.8pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Below SMA200 (0.94x), long-term trend not supportive. MACD histogram bearish (-1.15), momentum weakening. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.84% (CS: 20) | Weak |
| RSI_14 | 38.9 | Neutral |
| MACD Histogram | -1.15 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 0.960x | Below |
| vs SMA200 | 0.936x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $351.73
- **Stop Loss:** $337.85 (3.9% risk)
- **Target:** $379.49 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 72
- **Position Value:** $25,324.56
- **Portfolio %:** 25.32%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*